Why the study?
Long non-coding RNAs hold promise in mitigating diabetic cardiomyopathy, but the role and underlying mechanisms of FENDRR in DCM required investigation.
Is lncRNA FENDRR upregulated in diabetic cardiomyopathy and does its knockdown mitigate myocardial cell injury?
Is lncRNA FENDRR upregulated in diabetic cardiomyopathy and does its knockdown mitigate myocardial cell injury?
FENDRR is upregulated in diabetic cardiomyopathy and its knockdown mitigates myocardial cell injury in vitro, suggesting potential as a diagnostic marker and therapeutic target.
Answers are grounded in this paper and cite their sources.
FENDRR profiling may aid DCM risk assessment in T2DM; leaves open causal mechanisms and therapeutic targeting.
BACKGROUND: Long non-coding RNA (lncRNA) holds considerable promise in mitigating the onset and progression of diabetic cardiomyopathy (DCM). FENDRR was selected due to its reported involvement in cardiac apoptosis and inflammatory regulation, key pathways in DCM pathogenesis. This study investigated role and underlying mechanisms of FENDRR in DCM. METHODS: Type 2 diabetes mellitus (T2DM) patients were included and stratified by DCM status. One group was T2DM patients without DCM (n = 49), and the other was T2DM patients with DCM (n = 47).. Clinical data from both groups were compared. qRT-PCR was utilized to quantify serum FENDRR expression, with ROC analysis assessing its diagnostic value. A DCM cell model was established using high glucose-treated H9c2 cells. Flow cytometry and ELISA assays measured apoptosis, myocardial enzyme levels, antioxidant enzyme levels, and inflammatory. Dual-luciferase assays confirmed FENDRR-miR-296-5p and miR-296-5p-HMGA1 interactions. RESULTS: FENDRR was upregulated in DCM patients and high glucose-treated H9c2s (AUC = 0.888). si-FENDRR mitigated apoptosis in high glucose-stimulated H9c2 cells by inhibiting Bax and promoting Bcl-2 expression. si-FENDRR reduced myocardial enzymes release and inflammatory, and restored antioxidant enzyme levels. miR-296-5p was validated as a target of FENDRR, exhibiting an expression pattern opposite to that of FENDRR. miR-296-5p knockdown negated the positive effects of si-FENDRR on cardiomyocytes. HMGA1, a target gene of miR-296-5p, was upregulated in DCM patients and high glucose environments. CONCLUSIONS: This preliminary study uncovers the potential diagnostic value of FENDRR in DCM and explores its molecular mechanisms regulating myocardial cell injury via the miR-296-5p/HMGA1 axis.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: